2. Immunology/Inflammation Apoptosis Others
  3. Toll-like Receptor (TLR) TNF Receptor Interleukin Related IFNAR Drug Derivative
  4. VA06

VA06 is a derivative of QS-21 (HY-101092A) that retains potent adjuvant activity while significantly reducing toxicity. VA06 self-assembles into flexible worm-like micelles with continuously elongated nanostructures and enhanced drug-loading encapsulation capacity. VA06 induces antigen-specific antibody production, enhances the secretion of TNF-α, IFN-γ and IL-2 in CD4+ and CD8+ T cells, and promotes the expression of immune-related and antiviral-related genes in mature dendritic cells. VA06 does not require liposome formulation, which simplifies production and storage processes. VA06 can be used in the research of varicella-zoster virus infection and Mycobacterium tuberculosis infection.

For research use only. We do not sell to patients.

VA06

VA06 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

VA06 Related Antibodies

Top Publications Citing Use of Products

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms
TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

VA06 is a derivative of QS-21 (HY-101092A) that retains potent adjuvant activity while significantly reducing toxicity. VA06 self-assembles into flexible worm-like micelles with continuously elongated nanostructures and enhanced drug-loading encapsulation capacity. VA06 induces antigen-specific antibody production, enhances the secretion of TNF-α, IFN-γ and IL-2 in CD4+ and CD8+ T cells, and promotes the expression of immune-related and antiviral-related genes in mature dendritic cells. VA06 does not require liposome formulation, which simplifies production and storage processes. VA06 can be used in the research of varicella-zoster virus infection and Mycobacterium tuberculosis infection[1].

In Vitro

VA06 (0.5 mM; 1 min) in PBS solvent self-assembles into flexible wormlike micelles with continuous, elongated nanostructures[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

VA06 Related Antibodies
In Vivo

The VA06+MPL (BST02) formulation (5 μg VA06 + 5 μg MPL per dose; subcutaneous injection; administered on day 0 and day 14) induces significant OVA-specific humoral and T-cell immune responses in female C57BL/6J mice[1].
The VA06+MPL (BST02) formulation (5 μg VA06 + 5 μg MPL per dose; subcutaneous injection; administered on day 0 and day 14) induces robust VZV-gE-specific humoral and cellular immune responses in female C57BL/6J mice[1].
VA06 (5 μg per mouse; intramuscular injection; single administration) exhibits excellent in vivo muscle tolerance in male rats, with no reactogenicity detected[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (female, 6-8 weeks of age)[1]
Dosage: 5 μg VA06 + 5 μg MPL per dose
Administration: s.c.; Day 0 and Day 14
Result: Induced anti-OVA IgG titers of ≥1×1011 ng/mL, anti-OVA IgG1 titers of ≥1×109 ng/mL, and anti-OVA IgG2b titers of ≥1×106 ng/mL.
Induced 3.5% of CD4+ lymphocytes to produce TNF-α, 3% of CD4+ lymphocytes to produce IL-2, and 1.75% of CD8+ lymphocytes to produce TNF-α.\n
Induced VZV-gE-specific IgG, IgG1, IgG2c, and IgG2b antibody levels significantly higher than PBS control, with IgG levels slightly higher than AS01b.
Induced 2.75% of CD4+ lymphocytes to produce IFN-γ and 3% of CD4+ lymphocytes to produce TNF-α, and 1% of CD8+ lymphocytes to produce IFN-γ.
Animal Model: C57BL/6J (female, 6-8 weeks of age)[1]
Dosage: 5 μg VA06 + 5 μg MPL per dose
Administration: s.c.; two doses, 2 weeks apart
Result: Induced Mtb-M72-specific IgG, IgG1, IgG2b, and IgG2c antibody levels significantly higher than PBS control and QS-21+MPL group, with IgG, IgG1, IgG2b, and IgG2c levels higher than BST01.
Induced 3.5% of CD4+ lymphocytes to produce IFN-γ, 3% of CD4+ lymphocytes to produce TNF-α, and 1.25% of CD8+ lymphocytes to produce IFN-γ (all significantly higher than QS-21+MPL and BST01 groups).
Animal Model: Male rats[1]
Dosage: 5 μg VA06
Administration: intramuscular; single dose
Result: Showed no detectable reactogenicity or muscle tissue damage (tissue morphology comparable to PBS control and AS01b groups, and significantly less damage than QS-21+MPL group).
Molecular Weight

1194.49

Formula

C63H103NO20
SMILES

O[C@H]1[C@]2(C(O[C@H]3[C@H](O[C@@H]4O[C@@H](C)[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)CO5)[C@@H](O)[C@H]4O)[C@@H](O)[C@@H](NC(CCCCCCCCCCCCCCC(O)=O)=O)[C@@H](CO)O3)=O)[C@@H](CC(C)(C)CC2)C6=CC[C@@]7([H])[C@@]([C@]6(C)C1)(C)CC[C@@]8([H])[C@](C)(C=O)[C@@H](O)CC[C@@]87C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

VA06 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

VA06VA 06VA-06Toll-like Receptor (TLR)TNF ReceptorInterleukin RelatedIFNARDrug DerivativeTumor Necrosis Factor ReceptorTNFRILInterferon-α/β receptorInterferon-alpha/beta receptor Drug derivativeCD4+ T cellsCD8+ T cellswormlike micellesMPLQS-21mycobacterium tuberculosisvaricella-zoster virusmature dendritic cellsantigen-presenting cellsvaccine adjuvantInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
VA06
Cat. No.:
HY-182369
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.